pegfilgrastim + LY2523355
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer
Trial Timeline
May 1, 2008 → Jun 1, 2012
NCT ID
NCT01214642About pegfilgrastim + LY2523355
pegfilgrastim + LY2523355 is a phase 1 stage product being developed by Eli Lilly for Advanced Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01214642. Target conditions include Advanced Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01214642 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Cancer